ArticleCureus2025
Diagnosis and Treatment of Laryngeal Extranodal Natural Killer/T-cell Lymphoma.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extranodal natural killer (NK)/T-cell lymphoma (ENKL) is an aggressive subtype of non-Hodgkin lymphoma (NHL). Its presentation in the larynx is extremely rare and may mimic tuberculosis and squamous cell carcinoma. Laryngeal ENKL is a rare form of NHL, often diagnosed at an advanced stage with a poor prognosis despite chemoradiotherapy. We report the case of a 26-year-old female patient with an eight-month history of fever, cough, hoarseness, and dysphagia. Contrast-enhanced CT revealed a mass protruding from the left posterior pharyngeal wall. Immunohistochemistry confirmed the diagnosis of laryngeal ENKL. The patient received CHOP chemotherapy (cyclophosphamide 700 mg, doxorubicin 50 mg, vincristine 2 mg, dexamethasone 20 mg), which was later changed to DeVIC (dexamethasone 40 mg, etoposide 70 mg, ifosfamide 1,000 mg, carboplatin 200 mg) with local radiotherapy. After completing treatment, the patient was readmitted four months later with multiple episodes of fever, hemoptysis, and odynophagia. Due to the inability to place a nasogastric tube, a Witzel gastrostomy was performed. However, the patient died from non-oncological causes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.